Presentations From prIME Masterclass in NETs - priME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

Presentations From prIME Masterclass in NETs

A Multidisciplinary Interactive Workshop

Not a member of My prIME? Join now for instant access.

View downloadable slides for updates about the latest advances and emerging strategies in the management of neuroendocrine tumors (NETs) including epidemiology, clinical characteristics, natural history, pathophysiology, and current and emerging treatment strategies for patients with functioning and nonfunctioning NETs.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Nov 20, 2018

Expiration Date

Nov 20, 2019

Session I: Biology, Pathology, and Prognosis

Featured Expert

  • Ulrich-Frank Pape, MD, Charité University Hospital, Berlin, Germany

Featured Topic

Determining prognosis in NETs: Clinical, radiologic, and biologic markers—Are they really useful?

Featured Expert

  • Leo Hofland, PhD, Erasmus Medical Center, Rotterdam, the Netherlands

Featured Topic

Update on cellular pathways in NET behavior: Somatostatin receptor pathways

Featured Expert

  • Bertram Wiedenmann, MD, PhD, Charité University Hospital, Charité Virchow Campus Clinic, Berlin, Germany

Featured Topic

Update on genomics in NETs

Featured Expert

  • Jean-Yves Scoazec, MD, PhD, Gustave Roussy, Villejuif, France

Featured Topic

Interactive clinician-focused pathology workshop & 2017 classification updates

Session II: Imaging and Surgery

Featured Expert

  • Maxime Ronot, MD, PhD, Beaujon University Hospital, Clichy, France

Featured Topic

Imaging and image-guided therapy for gastroenteropancreactic (GEP) NETs

Featured Expert

  • Massimo Falconi, MD, University Vita-Salute San Raffaele, IRCCS San Raffaele Hospital, Milan, Italy

Featured Topic

Surgical challenges in NET management: Pancreatic NETs

Featured Expert

  • Reza Kianmanesh, MD, PhD, R. Debré University Hospital, Reims, France

Featured Topic

Surgical challenges in NET management: Intestinal NETs

Featured Expert

  • Sébastien Gaujoux, MD, PhD, Hospital Cochin, AP-HP, Paris Descartes University, Paris, France

Featured Topic

Surgical challenges in NET management: Liver metastases

Session III: Therapy and Patient Care

Featured Expert

  • Marianne Pavel, MD, University Hospital Erlangen, Erlangen, Germany

Featured Topic

Keynote lecture—Systemic therapy for NETs: Current options and challenges

Featured Expert

  • Giovanni Paganelli, MD, IRST-IRCCS, Meldola, Italy

Featured Topic

Radiopharmaceuticals in NETs: Current and future state of therapy

Featured Expert

  • Philippe Ruszniewski, MD, University of Paris VII, Beaujon Hospital, Paris, France

Featured Topic

Case-based clinical management discussions: Pancreatic NETs

Featured Expert

  • Dermot O’Toole, MD, FRCPI, St Vincent’s University Hospital, St James's Hospital
    Trinity College Dublin, Dublin, Ireland

Featured Topic

Case-based clinical management discussions: Intestinal NETs

Featured Expert

  • Jaume Capdevila, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Case-based clinical management discussions: Pulmonary NETs

Session IV: Improving Patient Outcomes and Research Strategies

Featured Experts

  • John Ramage, MD, MB, BS, FRCP, Hampshire Hospitals NHS Trust, Hampshire, United Kingdom
  • Catherine Bouvier, NET Patient Foundation, London, United Kingdom

Featured Topic

Quality of life and the patient experience

Featured Expert

  • Jaume Capdevila, MD, PhD, Vall d’Hebron University Hospital, Barcelona, Spain

Featured Topic

Keynote lecture—Clinical trials in NETs: How can we do better?

Session V: Developing Specialist Expertise

Featured Expert

  • Leo Hofland, PhD, Erasmus Medical Center, Rotterdam, the Netherlands

Featured Topic

Where are we going with our understanding and treatment of NETs in 2019? Basic Science

Featured Expert

  • Jean-Yves Scoazec, MD, PhD, Gustave Roussy, Villejuif, France

Featured Topic

Where are we going with our understanding and treatment of NETs in 2019? Diagnosis and pathology

Featured Expert

  • Bertram Wiedenmann, MD, PhD, Charité University Hospital, Charité Virchow Campus Clinic, Berlin, Germany

Featured Topic

Where are we going with our understanding and treatment of NETs in 2019? Treatment

Featured Experts

  • Dermot O’Toole, MD, FRCPI, St Vincent’s University Hospital, St James's Hospital
    Trinity College Dublin, Dublin, Ireland
  • Philippe Ruszniewski, MD, University of Paris VII, Beaujon Hospital, Paris, France

Featured Topic

prIME Points™ and closing remarks

This educational activity is designed for oncologists, endocrinologists, gastroenterologists, nuclear medicine specialists, and other healthcare providers involved and/or interested in the management of patients with neuroendocrine tumors (NETs).

After successful completion of this educational activity, participants should be able to:

  • Describe the epidemiology, clinical characteristics, and natural history of NETs
  • Understand the cellular pathways of relevance in NETs and the role of molecular pathology in patient management
  • Select appropriate therapy from the increasing range of therapeutic options available for first and subsequent lines of treatment
  • Identify the potential for novel therapeutic strategies in the treatment of NETs

This educational activity is supported by Ipsen.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Catherine Bouvier has disclosed that she has received grants or research support from IEL, Ipsen, Merck, Novartis, and Sirtex. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Capdevila has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Falconi has disclosed participation in company-sponsored speaker’s bureaus for Advanced Accelerator Applications, Celgene, Ipsen, Johnson & Johnson, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Gaujoux has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Hofland has disclosed that he has received grants or research support from Ipsen and Novartis. He has also disclosed receiving honoraria or consultation fees from Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Kianmanesh has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr O’Toole has disclosed receipt of grants/research support from AstraZeneca, Ipsen, Novartis, and Wyeth. He has disclosed receipt of honoraria or consultation fees from AstraZeneca, Ipsen, Novartis, Pfizer, and Roche. He has also disclosed participation in company-sponsored speaker’s bureaus for Ipsen and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Paganelli has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pape has disclosed that he has received grants or research support from Ipsen and Novartis. He has also disclosed receiving honoraria or consultation fees from Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Pavel has disclosed that she has received grants or research support from Ipsen and Novartis. She has also disclosed receiving honoraria or consultation fees from Ipsen, Lexicon, Novartis, and Pfizer. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.

Dr Ramage has disclosed that he has received research grants from Advanced Accelerator Applications and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ronot has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Ruszniewski has disclosed that he has received grants or research support from Ipsen. He has also disclosed receiving honoraria or consultation fees from Advanced Accelerator Applications, Ipsen, Keocyt, and Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Scoazec has disclosed honoraria for a promotional speaker’s bureau from Novartis. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

Dr Wiedenmann has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) –  consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference
  • Sanneke Koekkoek, RN (scientific content reviewer/planner) – no relevant financial relationships
  • Jessica Mastrodomenico, MPH (editorial content reviewer) – no relevant financial relationships

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.